Renal damage in type 2 diabetes exemplifies a complex, multisystemic disorder with substantial heterogeneity in clinical trajectory, histopathology, and molecular drivers. Traditional clinical markers, albuminuria and glomerular filtration rate, fail to capture this diversity because many patients follow atypical trajectories such as nonalbuminuric progression, rapid estimated glomerular filtration rate decline, or regression of albuminuria. Deep endotyping approaches integrating clinical dynamics, renal histopathology, and multi-omics profiling can define biologically distinct endotypes.
Renal damage in type 2 diabetes exemplifies a complex, multisystemic disorder with substantial heterogeneity in clinical trajectory, histopathology, and molecular drivers. Traditional clinical markers, albuminuria and glomerular filtration rate, fail to capture this diversity because many patients follow atypical trajectories such as nonalbuminuric progression, rapid estimated glomerular filtration rate decline, or regression of albuminuria. Deep endotyping approaches integrating clinical dynamics, renal histopathology, and multi-omics profiling can define biologically distinct endotypes.